Category Archives: Genetic Engineering

Article content

BUFFALO, N.Y., Oct. 06, 2022 (GLOBE NEWSWIRE) 22nd Century Group, Inc. (Nasdaq: XXII),a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies,announced today that James A. Mish, Chief Executive Officer, will present and host investor meetings at the 7th Annual Dawson James Small Cap Growth Conference being held Wednesday, October 12, 2022, at the Wyndham Grand Hotel in Jupiter, Florida.

The Company will host a group presentation at 10:30 am Eastern Time on October 12. A live and archived webcast of the presentation will be available for viewing under the Events Link at 22nd Century Groups Investor Relations website.

Institutional investors participating in the conference can request a meeting with management through their Dawson James representative or by contacting 22nd Century Groups investor relations team via investorrelations@xxiicentury.com.

About 22nd Century Group, Inc.22nd Century Group, Inc. (Nasdaq:XXII) is a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science. With dozens of patents allowing it to control nicotine biosynthesis in the tobacco plant, the Company has developed proprietary reduced nicotine content (RNC) tobacco plants and cigarettes, which have become the cornerstone of theFDAs Comprehensive Planto address the widespread death and disease caused by smoking. The Company received the first and only FDA MRTP authorization of a combustible cigarette in December 2021. In tobacco, hemp/cannabis, and hop plants, 22nd Century uses modern plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding to deliver solutions for the life science and consumer products industries by creating new, proprietary plants with optimized alkaloid and flavonoid profiles as well as improved yields and valuable agronomic traits.

Learn more atxxiicentury.com, onTwitter, onLinkedIn, and onYouTube.

Learn more about VLNattryvln.com.

Investor Relations & Media Contact:Mei Kuo22nd Century Group, Inc.Director, Communications & Investor Relationsmkuo@xxiicentury.com

Darrow Associates Investor RelationsMatt KrepsT: 214-597-8200mkreps@darrowir.com

Link:
22nd Century Group (Nasdaq: XXII) to Participate in the Dawson James Small Cap Growth Conference on October 12 - Financial Post

The 2022 study, published in Gastroenterology, evaluated whether fermentable fiber increased the risk of liver cancer in mice with a specific congenital defect. 90% of the mice showed no signs of cancer when fed a standard diet. But the mice who ate diets enriched with the fermentable fiber inulin became more likely to develop liver injury and liver cancer. The mice also had elevated bile acid (BA) levels, a marker that predicts liver cancer.

Inulin is a soluble fiber that occurs naturally in plant foods like raw onion, garlic, wheat, barley, and chicory root(per Medical News Today). When eaten in its natural form, inulin is considered safe for most people. But inulin is also artificially manufactured, either as chicory inulin or as high-performance (HP) inulin, which is made by removing some molecules from natural inulin. Food manufacturers add inulin to processed foods like protein bars, drinks, yogurt, and baked goods to replace sugar and fat and to improve texture.

WebMD considers inulin a beneficial prebiotic fiber that helps good bacteria grow in the gut, helping to maintain a healthy gut biome. But the 2022 study, along with another 2018 study by researchers at the University of Toledo, shows inulin increases the risk for liver cancer in some mice (via Genetic Engineering & Biotechnology News). Human studies are needed to determine if inulin has similar effects on people, but for now, it may be safer to limit your consumption of processed foods.

Read this article:
Study Finds Not All Fiber Is The Same And Some Can Be Hazardous To Your Health - Health Digest

A report published Wednesday exposes the "growing threat" of genetically engineered tree development around the world, with researchers urging a leading forest product certification body to maintain its longstanding ban on genetic modification.

"The convenience of trees that can survive glyphosate will likely result in the use of more glyphosate, more often."

"The global release of genetically engineered (GE or genetically modified) trees is closer than it has ever been," states the report, assembled by the Canadian Biotechnology Action Network (CBAN) and the Campaign to STOP GE Trees. "This advancement is a significant concern because the release of GE trees would pose serious threats to forests and other ecosystems, as well as to many local communities and Indigenous peoples. The environmental impacts could be irreversible."

The report documents the status of GE tree development worldwide to identify where the risk of GE tree use on plantations or release into the wild is most immediate. It comes ahead of the Forest Stewardship Council's (FSC) general assembly from October 9-14 in Bali, Indonesia.

The FSCa nonprofit headquartered in Germany that operates a global market-based certification program for forest productsis currently reconsidering its 27-year ban on GE trees, much to the chagrin of civil society groups around the globe.

As the report notes, the FSC and other so-called "sustainable forest management" organizations that certify products according to their own social and environmental standards are facing pressure from major corporations and university biotechnology researchers to allow GE trees in their certification programs.

Next month in Bali, FSC members will vote on two motions that, if approved, would help preserve the group's prohibition on genetic modification.

However, "if the Forest Stewardship Council decides to embrace genetic engineering, it will free the Brazilian pulp and paper company Suzano to begin planting its eucalyptus trees that are genetically engineered to tolerate glyphosate herbicides," warned Lizzie Daz of the World Rainforest Movement.

To date, the only genetically modified forest tree released commercially was a GE poplar tree in 2002 in China.

Despite opposition from nearly three dozen environmental and social justice groups in Brazil and several others across the world, the Brazilian government approved Suzano's application for a GE glyphosate-tolerant eucalyptus tree last November. As an FSC-certified company, Suzano cannot start commercial planting of its GE tree unless the FSC drops its ban on genetic modification or Suzano leaves the organization.

According to the report:

Suzano claims that this GE eucalyptus "will allow more efficient weed control with lowered chemical load and improved worker conditions." However, this promise was also made by the biotechnology industry for the use of GE herbicide-tolerant crops and it proved false. Herbicide use increased significantly with the use of GE herbicide-tolerant crops in North America and South America. Pesticide use in soybean production in Brazil increased three-fold between 2000 and 2012 after the introduction of GE (Roundup Ready) soy. Official statistics show rates of glyphosate use increased significantly in both Brazil and Argentina where glyphosate-tolerant soy is 85% and 100% of all soy grown respectively.

Glyphosate is used to clear the land of other plants in order to prepare tree plantation sites and it is also applied to new plantations in the first few years of growth. As observed with GE crops, the convenience of trees that can survive glyphosate will likely result in the use of more glyphosate, more often. In the case of eucalyptus plantations, it may also encourage ariel spraying of new plantations where direct spraying of plants on the ground is the current norm.

[...]

Glyphosate is now the most widely used herbicide ingredient in the world. Brazil's health agency, Anvisa, concluded that there are health risks for people exposed to glyphosate when it is applied to crops and stipulated a safe distance be kept from populated areas when using it. This is important because many small communities are surrounded by eucalyptus plantations, just as others are surrounded by GE glyphosate-tolerant soy monocultures. Pesticide use in Brazil with GE soy causes injury to thousands of people each year.

Contrary to claims made by agro-chemical giants, the report finds no evidence that the introduction of genetically modified trees designed to be more productive will lead to land conservation. The further expansion of tree plantationsalong with increased social conflictis the more likely outcome, the authors warn.

"Tree plantations are not forests: they do not support the same biodiversity as forest ecosystems," the report stresses. "They often deplete water resources, degrade and erode soil, and make extensive use of chemical pesticides. The ecological impacts of plantations are felt by local communities, who are often left without livelihoods, food, or water, with little recourse."

"In 2018, more than one thousand women from the rural Landless Workers Movement (MST) in Brazil took over a mill owned by the pulp and paper company Suzano," the report notes. "The women's key grievances included the depletion of critical freshwater resources and the contamination of water by aerial spraying of pesticides on eucalyptus plantations."

Other key findings include:

"Development of genetically engineered trees is advancing despite the serious risks to our forests and continued opposition around the world," lead author Lucy Sharratt of CBAN said in a statement. "Our report shows that genetically engineered trees are closer than ever to being released even though interest is limited to just a handful of companies and university researchers."

Nevertheless, "genetically engineered trees are not inevitable," Sharratt continued. "Even if the research is very far advanced, or even approved for planting, GE trees still might never make it to market. Genetic engineering in trees is technically challenging, extremely risky for the environment, and globally, it's very controversial."

The report also points out, however, that "just as the development of GE trees is advancing, government regulation is retreating," thereby increasing the risks that such trees will be released.

"Many national governments are reducing or removing their oversight of the field testing and commercial release of new genetically modified organisms," the authors write. "This report may be the last opportunity to get a snapshot of GE tree field testing around the world."

"The gaps in our understanding of genetic engineering, tree biology, and forest ecology conspire to build a profile of tremendous uncertainty," the report adds. "At the same time, the enormous ability of trees to spread pollen and seeds increases the reach of potential environmental and social impacts across national borders and in violation of Indigenous sovereignty."

"Genetically engineered trees would also perpetuate environmentally and socially destructive industrial plantation production that contributes to the climate crisis," the authors conclude. "Instead of moving towards a climate solution, genetically engineered trees would add unnecessary risks to forests, with possible irreversible impacts."

Read the original here:
Experts Sound Alarm Over 'Growing Threat' of Genetically Engineered Trees - Common Dreams

Scientists have genetically modified a strain of the herpes virus to act as a cancer-killing agent in humans. Findings from an initial human trial are encouraging, with the experimental treatment proving safe and promisingly effective.

Viruses are one of humanitys oldest enemies, as we have all seen over the pandemic, explained Kristian Helen from the Institute of Cancer Research. But our new research suggests we can exploit some of the features that make them challenging adversaries to infect and kill cancer cells.

Called oncolytic viruses, researchers have long explored the potential for these tiny invaders to be recruited as cancer-killing soldiers. With the advent of genetic engineering over recent years scientists have finally been able to engineer viruses so they help instead of harm.

In this new research scientists have looked to modify a strain of the herpes simplex virus. The genetically modified virus, called RP2, has been engineered to only multiply within cancer cells, causing them to essentially inflate and explode.

The virus is designed to be directly injected into tumors and also act as an immune system alarm, attracting the bodys own cancer-killing cells by producing molecules that spark immune activity.

Our study shows that a genetically engineered, cancer-killing virus can deliver a one-two punch against tumors directly destroying cancer cells from within while also calling in the immune system against them, said Kevin Harrington, a researcher working on the project.

Initial findings from the first Phase 1 trial testing the oncolytic therapy in 39 patients were announced at a recent medical conference in Europe. Three of nine patients testing the viral therapy on its own saw their tumors shrink, while seven of the remaining 30 saw treatment benefits in combination with other immunotherapy.

This Phase 1 trial was primarily focused on establishing whether the treatment is safe, and no serious adverse effects were detected. Because it was just a safety trial the patients recruited spanned a number of different cancer types, so future trials will better target the most effective cancers for this therapy.

It is rare to see such good response rates in early-stage clinical trials, as their primary aim is to test treatment safety and they involve patients with very advanced cancers for whom current treatments have stopped working, said Harrington. I am keen to see if we continue to see benefits as we treat increased numbers of patients.

Source: The Institute of Cancer Research

View post:
Herpes virus genetically engineered to kill cancer - New Atlas

One of the leading causes of blindness in developed nations is neurodegenerative diseases of the retina. Therapeutic treatments are often unavailable, despite their critical role in enhancing patients lives. Significant interest existed in developing gene therapies for a group of diseases for which the underlying genes had already been identified; these diseases primarily affected photoreceptors. But gene-indepdendent approaches were required depending on the type and severity of the disease. Researchers are exploring several potential methods to slow the spread of disease or preserve retinal function. Neuroprotection, direct reprogramming of damaged photoreceptors, non-coding (ribonucleic acid) RNAs, optogenetic strategies for creating artificial photoreceptors, and cell replacement therapies are examples of interventions. Recent advances have been made, such as the first optogenetic application to a blind patient whose visual function was partially recovered by targeting retinal ganglion cells. RPE (Retinal Pigment Epithelium) cell transplantation therapies are also being studied in clinics, and they hold great promise for restoring sight to the visually impaired. Human embryonic stem cells were used to create these cells. There has been extensive testing of photoreceptor replacement therapies in pre-clinical models. Taking advantage of advances in genetic engineering, optogenetics, and stem-cell research, this is just the beginning of promising new cures. Here is a summary of the current state of gene-independent therapeutics and a highlight of the recent advances that have been made. Since photoreceptors are essential for light perception but are particularly susceptible to degenerative diseases, they are the primary focus of this research.

Source: sciencedirect.com/science/article/pii/S1350946222000258

Read more:
Gene-independent Therapeutic Interventions in Degenerating Photoreceptors - Physician's Weekly

The NationalBioengineeredFood Disclosure Standard(NBFDS) which narrowlydefines bioengineered foods as those that contain detectable genetic material that has been modified through certain lab techniques and cannot be created through conventional breeding or found in nature kind of shot in the middle and missed every constituency,"observes Nate Ensrud, VP, US technical services, certification, and food safety solutionsatFoodChain ID, which helps firms to comply with the standard.

For some stakeholders in the natural foods industry, he says,it missed the mark,both in scope (the definition fails to capture thousands of products that have been produced with genetic engineering) and application (many objected to bioengineered vs GMO as the chosen terminology and the option to use digital disclosures on food labels).

For other stakeholders who believeslapping a blanket statement about bioengineering (which has thousands of different applications) on a jar of pasta sauce is about as useful as saying 'science was used to make this product," the NBFDS in its current form is just acostlybureaucratic headachewithout any obvious consumer benefit.

A major sticking point is the definitionof bioengineered, which excludes meat and dairy from animals fed GM feed, incidental additives, and highly refined oils and sweeteners made from GM crops such as soybean oil and high fructose corn syrup if they contain no detectable modified DNA.

Gene-edited foods, in turn, occupy something of a grey area. They may not contain detectable genetic material that has been modified through traditional rDNA techniques, but how easy is it for a third party to determine if gene-edited material meets the definition ofcannot be created through conventional breeding or found in nature?

Back in the day, says Ensrud, We were mostly talking about a series of crops that very obviously had genes inserted to express different traits.

"But since then, theres been a substantial proliferation of gene-edited products, products made using synthetic biology and so on, and while the [alternative meat, egg, and dairy]movement used to be pretty aligned, this is not the case anymore [as anyone following the social media debate about whether 'biotech' companies should be allowed to exhibit at Natural Products Expo West can see].

For example, under the NBFDS, firms deployingsynthetic biologyto re-tool the DNA of microbes to produce everything from flavors, sweeteners, and colors to animal-free collagen, egg, or dairy proteins are not required to label their ingredients as 'bioengineered' if there is no detectable level of the genetically modified host micro-organism in the final product.

This means that milk, ice cream, or cream cheese containing Perfect Days animal-free whey protein, which is expressed by a genetically engineered strain of fungi in a fermentation tank; or beverages containing Cargills EverSweet Reb M sweetener, made by GM bakers yeast, will not trigger a bioengineered label, if no GM material is detectable in the final ingredient.

However, burgers containing Motif FoodWorks 'meaty' animal-free heme protein myoglobin which is also made in a fermentation tank using a pichia pastoris yeast strain probably will trigger a bioengineered disclosure under the NBFDS, as trace amounts of the host microbe may be in the final product, says the company.

But even for exactly the same ingredient - myoglobin - no two companies producing this via fermentation are necessarily subject to the same labeling requirements when it comes to bioengineered food, saysBelgian startup Paleo, which has engineered a strain of pichia pastoristo express myoglobin in an extra-cellular fashion (it's secreted outside the cell).

This means its easier to separate myoglobin from the yeast cells during downstream processing and purification, such that Paleo'smyoglobin would not trigger bioengineered labeling in the US and would not be subject to EU GMO regulations, argues co-founder Hermes Sanctorum.

"Weve tested our heme proteins through PCR and there is no recombinant DNA whatsoever in our products.

The difficulty for companies trying to navigate this minefield is that the NBFDS doesn't really talk much about microbes"or much less explain how you label them with the exception of something like certain probiotics where genetically engineered bacteria might be the end product itself [rather than a production platform for something else], notes Ensrud.

To further complicate matters, he says:Then theres a really vague section of the of NBFDS that says if a company has actual knowledge its using something bioengineered, even if a food is not on the BE list, it is supposed to make a disclosure, which feels like a throwaway line, but how do you determine that?

He adds:We don't know a lot about how this will be enforced because the USDA has been clear that they're not going to be proactively enforcing this, but will be reliant on complaints. And so far, we havent seen very many well-structured complaints that can help us say, these are the areas that companies are going to challenge, and I don't know that it's going to be one of the first areas people think about because microbes are not included in the list of bioengineered foods.

USDA's Agricultural Marketing Service (AMS) has so farreceived just seven complaints alleging violations of the standard, said a spokesperson.

"If anyone suspects a violation may have occurred, they can file a written complaint with the AMS administrator by mail or on the AMS website. The administrator determines whether reasonable grounds exist for an investigation of the complaint, and if so, may request records from the entity responsible for disclosure. Based on those records, AMS will make its findings available to the regulated entity and provide them with an opportunity for a hearing. After the hearing, or if a hearing was not requested, once AMS has finalized its findings, AMS will make public a summary of the results of the investigation."

AMS does not have the authority to issue a recall or impose civil penalties for violations of the standard. However, states may adopt identical requirements and impose remedies for violations of their standards, explained the spokesperson. "USDA is not aware that any state has acted to impose such remedies."

The detectability factor makes practical sense, argue many stakeholders: if there's noGMOactually in the food, why should you have to label it?

But for organizations such as the Non-GMO Project that take issue withgenetic engineering in the food supply chain per se, whether there's actually any 'modified genetic material' left in soybean oil or a natural flavor is hardly the point, notes Ensrud.

Their goal is to establish a GMO-free supply chain, and so the gap between their definition of what should be labeled GMO and the NBFDS is an ocean wide.

Having said that, the Non-GMO Project has arguably gained traction as a result of all this confusion, given that foods without bioengineered labels are not necessarily Non-GMO given the narrow scope of the federal law, prompting shoppers that care about avoiding genetic engineering to seek outthe butterfly logo while shopping if they want to be sure.

So what about disclosure options, which like everything else in theNBFDS, have generated a lot of controversy? The standardpermits multiple options:

Aspects of the digital disclosure options have just been successfully challenged in a lawsuitbrought by the Center for Food Safety and others, with a court sending USDA back to the drawing board to make revisions consistent with Congressional requirements around consumer access.

So what does this mean for companies currently using the QR code or text message option? According to Ensrud, We did see some companies choose to use the QR code, but not a large majority by any means. The ones that were choosing QR codes told us they liked the flexibility, as perhaps they were still trying to remove some bioengineered foods from their supply chain and would move from having to disclose to not having to disclose, which would require a change in labels, which can be costly and laborious.

The opposite is also possible. If a company has to make an emergency shift from a non-GMO source to a GMO source for an ingredient [not that unusual given current supply chain volatility], it would likely change the labeling requirements. For companies that have less settled supply chains, this change in requirements could make things more difficult.

Sam Jockel, a senior associate at law firm Alston & Bird, noted that There is still an opportunity for either USDA or the plaintiffs in this case to appeal theruling, which I am watching for.

According to George Kimbrell, legal director at the Center for Food Safety, which filed the lawsuit challenging many aspects of the NBFDS, The Court did not set a deadline, but under law agencies cannot unduly delay such action and must complete it in a reasonable time.

Should the order ultimately stand, said Jockel,it appears that USDA would have discretion in terms of timing as the court did not set any deadlines for USDA to conduct its post-remand proceedings.

For those who think this means that the QR code will go away, added Jockel, The statute passed by Congress requires an electronic/digital link disclosure as one of the options along with the text and symbol, so the QR code option is not going away.

The Consumer Brands Association said it is still reviewing the court order, but added:"We plan to stay engaged during the forthcoming rulemaking and legal process, especially considering the potential impact on the companies using QR codes or texts. Consumer Brands will also continue supporting the valuable role digital disclosures play in boosting consumer transparency through programs like SmartLabel.

Jockel also noted that the scope of the products that require mandatory disclosure is actually subject to change.

Companies will want to watch for any updates to thelist of BE Foodsas AMS is required to review and consider updates on an annual basis. As the judges order put it in reference to the agencys regular updates to the List of BE Foods, AMS did not ignore the likelihood of progress. As evidence of that, the agency is currently proposing to expand the list to include insect-resistant sugarcane.

Greg Jaffe, biotechnology project director at the Center for Science in the Public Interest (CSPI), told us that an informal surveyconducted in his local Giant grocery store earlier in the year found that almost no companies use the symbol on the package with most seeming to opt for the bioengineered food or contains a bioengineered food ingredient option, although several brands had adopted QR codes.

My informal survey also found many foods disclose even though they probably only have highly refined ingredients, so companies are clearly erring on the side of giving more information to the consumer than might be required.

So has the law helped consumers make informed choices? Or are blanket references to bioengineered foods just wallpaper to busy shoppers?

I think that the law has provided consumers who want to know this information, more information than they would receive without the law, said Jaffe, who described it as a step in the right direction in terms of transparency, in part because companies were not providing this information voluntarily anywhere for the consumer who wanted it.

He added:I dont think many consumers look for this information or make purchasing choices based on it. With that said, for many consumers, knowing that there is transparency and information is available is important (i.e. knowing that information that some people might want is not hidden or inaccessible).

Asked about the growing number of ingredients produced by genetically engineered microbes, he said:Many ingredients made with engineered organisms also will not require disclosure, but I think it is important that those companies are transparent and provide information to consumers about the origin of the ingredients in their products, whether or not it has to be disclosed as bioengineered.

Being transparent with consumers will build trust, educate consumers about the use of biotechnology in foods, and allow for consumer choice.

Further reading:

Continue reading here:
SPECIAL REPORT: Bioengineered food labeling: 'They kind of shot in the middle and missed every constituency' - FoodNavigator-USA.com

A progressive report titled Genome Editing Market launched by Fior Markets contains extensive genuine information on the market which connects with the clients to plan the future interest and perform the right implementation. The report extensively researches global Genome Editing market insights, dynamics, trends, and future opportunities. It presents an in-depth analysis that has been projected to assemble substantial returns by the end of the forecasted timeline from 2022 to 2029. The report has extensively investigated and statistically analyzed vital market elements.

The report guides every businessman for their future innovation and moves the business forward by providing all market data, insight, and expert analysis with easily digestible information. The report comprises an in-depth analysis of the global Genome Editing industry which aims to deliver a comprehensive market intelligence study associated with major market components. Our dedicated team of experts has delivered this report with accurate data extracted from trusted sources. The market report delivers detailed information about the alterations in the types of product, its innovation, and its advancements.

Click Here to Download and Understand Latest Key Trends: https://www.fiormarkets.com/report-detail/419241/request-sample

In the segmentation analysis, the report provides an assessment of all the segments such as the type of product, application, and region. The segments are studied with regard to their market share, turnover, growth rate, and other vital factors. The global Genome Editing market report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, and recent developments in both historic and present contexts. The research comprises primary information about the products.

The prominent players of the market are:

Thermo Fisher Scientific, Horizon Discovery Limited, GenScript, Eurofins Scientific, Editas Medicine, CRISPR Therapeutics, Oxford Genetics, Synthego, Vigene Biosciences, Integrated DNA Technologies, OriGene Technologies, Transposagen Biopharmaceuticals, Agilent Technologies, Genecopoeia, and Precision Biosciences,among others.

Global Genome Editing Market Analysis and Forecast, By Technology: ZFN, TALENs/MegaTALs, CRISPR/Cas9, Others

Global Genome Editing Market Analysis and Forecast, By Application: Cell Line Engineering, Plant Genetic Engineering, Animal Genetic Engineering, Other Applications

The countries covered in the global Genome Editing market report are:

North America (U.S. , Canada, Mexico), Europe (Germany, France, U.K., Italy, Spain, Rest of the Europe), Asia-Pacific (China, Japan India, Rest of APAC), South America (Brazil and Rest of South America), Middle East and Africa (UAE, South Africa, Rest of MEA).

The report covers the dominating players along with their market share in the global Genome Editing market. This section of the study document reveals a complete profile of the companies with capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and technological developments. It contains an analysis of competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Browse Full Report with TOC & List of Figure: https://www.fiormarkets.com/report/genome-editing-market-by-technology-zfn-talens-megatals-crispr-cas9-others-419241.html

Reasons To Buy The Report:-

Then, it includes supply-demand statistics and segments that constrain the growth of an industry. Additionally, the report provides market drivers and challenges & opportunities for the overall global Genome Editing market in the particular provincial sections. The industry intelligence study of the global Genome Editing market covers the estimation size of the market each in phrases of value and volume. The report explains country-wise consumption and market size of the market. This study covers the inside and out factual examination and the market elements and requests which give an entire situation of the business.

About Fior Markets

Fior Markets is a futuristic market intelligence company, helping customers flourish their business strategies and make better decisions using actionable intelligence. With transparent information pool, we meet clients objectives, commitments on high standard and targeting possible prospects for SWOT analysis and market research reports. Fior Markets deploys a wide range of regional and global market intelligence research reports including industries like technology, pharmaceutical, consumer goods, food and beverages, chemicals, media, materials and many others.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@fiormarkets.comWeb: http://www.fiormarkets.com

Go here to see the original:
Genome Editing Market 2022-2029 : Industry Projections Featured by Existing Research Methodologies and Assumptions 2029 The Colby Echo News - The...

Its a great honor for Creative Biolabs to participate and exhibit at the 13th Annual World Bispecific Summit and showcase the one-stop bispecific antibody solutions covering services and products involved in the whole pipeline of antibody discovery.

New York, USA September 28, 2022 The 13th World Bispecific Summit gathering of bi-, tri-, and multispecific drug discovery and development scientists, has come to an end. With years of devotion to the advancement of biotechnology, Creative Biolabs is highly honored to exhibit at this great event on September 20 and would like to take this opportunity to thank all of clients and partners for stopping by booth #2 this year, and to thank the host, Hanson Wade, as well as the presenters and participants for making this summit a success!

The on-site scientist team elaborately prepared gifts and brochures and hope that all the guests enjoyed their visits and came away with relevant solutions to their inquiries. At the exhibition, Creative Biolabs also presented one-stop bispecific antibody (BsAb) solutions covering the services involved in the whole pipeline of antibody discovery, including but not limited to:

BsAb design: target-based and MOA-based design

BsAb engineering: bispecific fusion, BsAb conjugates, bispecific IgG generation, etc.

BsAb purification: protein A/G/L chromatography, tag-based purification, etc.

BsAb analysis: biochemistry characterization, stability analysis, PK/PD analysis, etc.

BsAb manufacturing: genetic engineering, chemical conjugation, hybrid-hybridoma, etc.

The dedicated team is ready to go above and beyond to support clients projects with custom BsAb products, as well as a full list of recombinant antibody products and antibody engineering services.

We appreciate the critical role that academic and industrial scientists play in the path of improving human health as they diligently pursue further scientific innovation and discovery. We would love to participate in these events to meet and connect with more researchers, and we are also dedicated to promoting biotech research by providing trustworthy products, services, and innovative ideas. said a scientist from Creative Biolabs at the 13th World Bispecific Summit.

Explore innovative BsAb solutions and stay up-to-date on the upcoming events at https://www.creative-biolabs.com/bsab.

About Creative Biolabs

With more than a decade of exploration and expansion, Creative Biolabs has been dedicated to offering services on antibody discovery, engineering, production, and analysis. Especially, the bispecific antibody (BsAb) team has gathered a collective of experienced scientists committed to providing high-quality services to customers all over the world, covering BsAb design, purification, engineering, manufacturing, and BsAb analysis service. Besides, a variety of standard or customized BsAb products are also available for different research applications.

Media ContactCompany Name: Creative BiolabsContact Person: Candy SwiftEmail: Send EmailPhone: 1-631-830-6441Country: United StatesWebsite: https://www.creative-biolabs.com/bsab

See the article here:
Creative Biolabs Unveils One-Stop BsAb Solutions at 13th Annual World Bispecific Summit - Digital Journal

ReportLinker

Protein therapeutic medicines are a class of pharmaceuticals used to treat a range of illnesses, including cancer, metabolic, hematological, immunological, hormonal, genetic, contagious diseases, and others.

New York, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Protein Therapeutics Market Size, Share & Industry Trends Analysis Report By Product, By Application, By Regional Outlook and Forecast, 2022 2028" - https://www.reportlinker.com/p06322275/?utm_source=GNW These medications could greatly enhance human health. Protein distribution in appropriate amounts to the body to enable the precise functioning of various glands, as well as other organs in the body, is the basic concept behind protein therapy, which is conceptually related to gene therapy.

Genetically modified versions of naturally produced human proteins are called therapeutic proteins. They can be utilized to swap out proteins that are defective or lacking in a particular condition. They can also increase the supply of a helpful protein, which helps lessen the effects of chemotherapy or sickness. The proteins produced by genetic engineering can be made to closely match the natural proteins they are meant to replace, or they can be improved by the addition of sugars and other compounds that prolong the proteins activity.

A protein that is defective or lacking in a certain condition can be replaced with therapeutic proteins. They can also increase the bodys production of a helpful protein to lessen the effects of illness or chemotherapy. The proteins produced by genetic engineering may closely resemble the natural proteins they are intended to replace, or they may be improved.

Covid-19 Impact Analysis

The COVID-19 pandemic severely hampered the economy all over the world. A number of businesses were significantly demolished by the abrupt emergence of the pandemic. Moreover, several manufacturing and production facilities were closed owing to the outbreak due to the lockdown imposed by various governments within their countries. The protein therapeutics market was also disrupted in the initial period of the pandemic. Lockdown caused major delays within the development and delivery of crucial medical supplies. Attributed to this, the production of therapeutic protein was impeded.

Market Growth Factors

An increase in the cases of cancer across the world

One of the major factors that are driving the growth of the protein therapeutics market is the expansion in the prevalence of various types of cancer all over the world. Any disease that can affect any region of the body is referred to as cancer. Neoplasms and malignant tumors are other words that are used to denote this disease. One characteristic of cancer is the quick development of aberrant cells that expand outside of their normal borders, infiltrate other body components, and eventually move to other organs. This process is known as metastasis. The main reason why cancer patients die is because of widespread metastases within their bodies.

Rising focus of governments and regulatory bodies in accelerating the process of approval for this practice

A significant number of people in various developed, as well as developing nations who suffer from uncommon and complex diseases, depend on plasma-derived therapies every day as essential, life-saving medications. The need for these treatments, in particular immunoglobulins, has grown significantly and is still growing on a global scale. Plasma-derived therapies are treatments made from human plasma through a fractionation procedure in which the pertinent plasma proteins are isolated. The single largest component of human blood is called plasma, which is made up of proteins, salts, enzymes, and water. Primary and secondary immunodeficiencies, bleeding disorders, inhibitor deficiencies, and other rare diseases are all treated with plasma-derived medicines.

Market Restraining Factors

High manufacturing and administration cost

A major challenge in the growth of the protein therapeutics market is the high cost of protein therapies. Because of high product prices, some therapies that patients need for a speedy and complete recovery are no longer available. In several nations, prices are additionally governed by law. Through their authority over national healthcare organizations, which can cover a significant portion of the cost of distributing drugs to consumers, government bodies restrict costs.

Product Outlook

On the basis of Product, the Protein Therapeutics Market is segmented into Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, and Follicle Stimulating Hormone. In 2021, the Insulin segment garnered a significant revenue share of the protein therapeutics market. The rise in the growth of the segment is majorly attributed to the increasing cases of diabetes all over the world. Insulin is a natural hormone, which is produced by the pancreas. The lack of production of this hormone is the factor that stimulates the diabetes level of the human body.

Application Outlook

By application, the Protein Therapeutics Market is segregated into Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders, and Others. In 2021, the metabolic disorders segment procured the biggest revenue share of the protein therapeutics market. The rise in the growth of the segment is due to the exponential demand for high-quality medications and adaptable therapies for the treatment of diseases, particularly diabetes, which is anticipated to support the segments growth.

Regional Outlook

Region-wise, the Protein Therapeutics Market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. In 2021, North America held the largest revenue share of the protein therapeutics market. This is ascribed to an increase in the incidence of chronic diseases, the use of cutting-edge treatments, the presence of important players, and an increase in healthcare spending in the area. Moreover, North American countries are early adopters of several new technologies and approaches.

The major strategies followed by the market participants are Acquisitions. Based on the Analysis presented in the Cardinal matrix; Johnson & Johnson and Pfizer, Inc. are the forerunners in the Protein Therapeutics Market. Companies such as Merck & Co., Inc. Amgen, Inc., Eli Lilly and Company are some of the key innovators in Protein Therapeutics Market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Baxter International, Inc., Amgen, Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Merck & Co., Inc., Johnson & Johnson (Janssen Global Services, LLC), Pfizer, Inc., Novo Nordisk A/S and Sanofi S.A.

Recent Strategies Deployed in Protein Therapeutics Market

Partnership, Collaboration and Agreements:

Aug-2022: Merck came into a collaboration with Orna Therapeutics, a biotechnology company. Following this collaboration, the companies would work on the discovery, development, and commercialization of multiple programs, encompassing therapeutics and vaccines in the sector of infectious disease and oncology.

Mar-2022: Novo Nordisk joined hands with Massachusetts Institutes of Technology and Brigham and Womens Hospital. Through this collaboration, the company aimed to leverage the distinct prospect to bring new transformational solutions to patients by utilizing its distinct capabilities.

Jan-2022: Amgen teamed up with Amgen Generate Biomedicines, a therapeutics company. Under this collaboration, the companies aimed to develop and manufacture protein therapeutics to address 5 clinical ailments.

Jan-2022: Merck teamed up with Absci, the drug, and target discovery company. Following this collaboration, Merck aimed to leverage Abscis platform to utilize its compelling opportunity intending to develop new biologic candidates as well as explore complex protein expression.

Aug-2021: Eli Lilly and Company joined hands with Lycia Therapeutics, a biotechnology company. Following this collaboration, the companies aimed to focus on the development, manufacturing, and marketing of new targeted therapeutics leveraging the proprietary lysosomal targeting chimera protein degradation technology of Lycia.

Sep-2020: Merck collaborated with Seattle Genetics, an American biotechnology company. With this collaboration, the companies aimed to further expand the oncology portfolio of Merck in order to enhance the lives of cancer patients.

Acquisition and Mergers:

Jun-2022: Pfizer took over ReViral, a privately held, clinical-stage biopharmaceutical company. Through this acquisition, the company aimed to integrate RSV investigational treatments of ReViral into its portfolio in order to acquire an offering of promising therapeutic candidates.

Nov-2021: Pfizer took over Trillium Therapeutics, a clinical-stage immuno-oncology company. This acquisition aimed to offer an impressive portfolio, including biologics, to Pfizer

Jul-2021: Amgen took over Teneobio, a clinical-stage biotechnology company. With this acquisition, the company aimed to leverage Teneobios antibody platform in order to complement its prevailing capabilities. Moreover, the company also aimed to gain a diverse range of building blocks that can be created into new multispecific therapeutics.

Jul-2021: Eli Lilly and Company completed its acquisition of Protomer, a pre-clinical stage biotechnology company. Under this acquisition, the company aimed to help Protomer in enhancing its diabetes range with its innovative technology.

Feb-2021: Merck took over VelosBio, a privately held clinical-stage biopharmaceutical company. Through this acquisition, the company aimed to boost its expanding oncology portfolio while also strengthening its long-term growth potential.

Aug-2020: Johnson & Johnson completed its acquisition of Momenta Pharmaceuticals, a biotechnology company. This acquisition aimed to strengthen Janssens position in the autoimmune diseases sector and offer a major catalyst for sustained growth of the company.

Approvals and Trials:

Sep-2020: Baxter International received the US FDA approval for its Clinimix and Clinimix E. The new formulations aimed to complement the offerings of medical formulations with their higher protein content.

Scope of the Study

Market Segments covered in the Report:

By Product

Monoclonal Antibodies

Human Growth Hormone

Fusion Protein

Insulin

Erythropoietin

Interferon

Follicle Stimulating Hormone

By Application

Metabolic Disorders

Immunologic Disorders

Hematological Disorders

Cancer

Hormonal Disorders

Genetic Disorders

Others

By Geography

North America

o US

o Canada

o Mexico

o Rest of North America

Europe

o Germany

o UK

o France

o Russia

o Spain

o Italy

o Rest of Europe

Asia Pacific

o China

o Japan

o India

o South Korea

o Singapore

o Malaysia

o Rest of Asia Pacific

LAMEA

o Brazil

o Argentina

o UAE

o Saudi Arabia

o South Africa

o Nigeria

o Rest of LAMEA

Companies Profiled

Abbott Laboratories

Baxter International, Inc.

Amgen, Inc.

F. Hoffmann-La Roche Ltd.

Eli Lilly And Company

Merck & Co., Inc.

Johnson & Johnson (Janssen Global Services, LLC)

Pfizer, Inc.

Novo Nordisk A/S

Sanofi S.A.

Unique Offerings

Original post:
The Global Protein Therapeutics Market size is expected to reach $490.2 billion by 2028, rising at a market growth of 6.9% CAGR during the forecast...

DUBLIN, Sept. 28, 2022 /PRNewswire/ --The "Synthetic Biology Market Size, Share, Trends, By Technology, By Tools, By Application, By End-use, and By Region Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

According to a new report, the Synthetic Biology Market size was valued at USD 9.26 Billion in 2021 and is estimated to exceed USD 75.9 Billion in terms of revenue, at a CAGR of 26.3% through 2030. Synthetic biology is an emerging field of science that deals with the design and construction of artificial biological systems for various applications. The market for synthetic biology is expected to grow at a rapid pace owing to the increasing demand for synthetic genes, proteins, and other biomolecules in the pharmaceutical and biotechnology industries.

Products produced by synthetic biology are used in pharmaceutical and biotechnology research, as well as industrial applications. Increasing government funding for synthetic biology research and the ever-expanding application areas of synthetic biology are the major drivers of this market.

Synthetic biology has a potential in DNA sequencing, genetic engineering, and other biotechnology applications. It is anticipated that the demand for synthetic biology will rise in the pharmaceutical and biotech industries for the development of new therapeutic proteins and designer microbes.

Increased amount of study data generation with dipping prices of DNA sequencing, rise in government funding and initiatives, and need for efficient disease management are the prominent drivers of the synthetic biology market. In addition, new applications in healthcare and pharmaceutical industry is another significant factor that is anticipated to fuel the growth of this market during the forecast period.

Market Dynamics

Market Drivers

Rapid Technological Advancements in the Field of Synthetic Biology

Diverse Range of Synthetic Biology-Based Applications Leading to Widespread Adoption in the Biotechnology and Pharmaceutical Industries

Rising Investments Toward Research & Development (R&D) Activities for Synthetic Biology-Based Research

Story continues

Market Restraints

Potential Biosafety, Biosecurity, and Ethical Issues Related to the Unintended or Deliberate Misuse of Synthetic Biology Techniques

Stringent Government Regulations & Guidelines

Market Segmentation

Technology Outlook (Revenue, USD Billion; 2019-2030)

Tools Outlook (Revenue, USD Billion; 2019-2030)

Application Outlook (Revenue, USD Billion; 2019-2030)

Medical & Healthcare Application

Artificial Tissue & Tissue Regeneration

Environment & Agriculture

Bioprocess Industry

End-use Outlook (Revenue, USD Billion; 2019-2030)

Regional Outlook (Revenue, USD Billion; 2019-2030)

North America

U.S.

Canada

Mexico

Europe

Germany

U.K.

France

Italy

Spain

Sweden

BENELUX

Rest of Europe

Asia-Pacific

China

India

Japan

South Korea

Rest of APAC

Latin America

Brazil

Rest of LATAM

Middle East & Africa

Saudi Arabia

UAE

South Africa

Israel

Rest of MEA

Key Topics Covered:

Chapter 1. Market Synopsis

Chapter 2. Executive Summary

Chapter 3. Indicative Metrics

Chapter 4. Synthetic Biology Market Segmentation & Impact Analysis

Chapter 5. Synthetic Biology Market By Technology Insights & Trends

Chapter 6. Synthetic Biology Market By Tools Insights & Trends

Chapter 7. Synthetic Biology Market By Application Insights & Trends

Chapter 8. Synthetic Biology Market By End-use Insights & Trends

Chapter 9. Synthetic Biology Market Regional Outlook

Chapter 10. Competitive Landscape

Chapter 11. Company Profiles

Companies Mentioned

Amyris Inc.

Ginkgo Bioworks

Codexis Inc.

Novozymes AG

Twist Biosciences

GenScrip Corporation.

Merck KGaD

Codex DNA Inc.

Eurofins Scientific Inc.

Amgen Inc.

For more information about this report visit https://www.researchandmarkets.com/r/vkyme3

Media Contact:

Research and MarketsLaura Wood, Senior Managerpress@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470For U.S./CAN Toll Free Call +1-800-526-8630For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

Cision

View original content:https://www.prnewswire.com/news-releases/global-synthetic-biology-market-2022-diverse-range-of-synthetic-biology-based-applications-leading-to-widespread-adoption-301635743.html

SOURCE Research and Markets

Link:
Global Synthetic Biology Market 2022: Diverse Range of Synthetic Biology-Based Applications Leading to Widespread Adoption - Yahoo Finance